Abstract Details

Title Efficacy of Oral Rifampicin in Multiple System Atrophy

Topic Movement Disorders

Presentation(s) P04 - (-)

Poster/Presentation
Number 159

Objective

Background BACKGROUND: We previously reported a clinical trial using rifampicin on 17 patients with MSA at the AAN 63rd Annual Meeting. This is a follow-up study on a larger number of patients.

Design/Methods DESIGN/METHODS: Thirty-three patients with MSA were enrolled (15 MSA-C and 8 MSA-P subjects). At trial entry, all subjects were assessed with International Cooperative Ataxia Rating Scale (ICARS), Unified Parkinson's Disease Rating Scale (UPDRS) and 6-minutes walk (6MW) to rate ataxia, parkinsonism, and general activity, respectively. We performed a linear regression analysis between the performance in each test and the disease duration. Each participant took 450mg of rifampicin every morning for 6 months, and then was evaluated with the same battery. The efficacy of rifampicin was evaluated by changes in regression slopes between the entry and the end of the trial. Five MSA subjects who were followed-up without taking rifampicin comprised the reference group.

Results RESULTS: Nineteen subjects completed the trial, and five are still underway. Nine subjects (27.3%) discontinued during the trial. We confirmed that ICARS and 6MW were both reliable parameters assessing the magnitude of natural progression of MSA: ICARS scale increased 5.28 points/year (yr) (R2=0.45) and 6MW decreased 61.2 meters/yr (R2=0.45). UPDRS was unreliable among the present cohort. Both ICARS and 6MW after the trial showed progression values comparable to those at entry (ICARS 4.91 points increase/yr; 6MW: 63.6 meter decrease/yr). The progression was more rapid in the reference group (ICARS: 15.6 points increase/yr; 6MW: 106.8 meter decrease/yr).

Conclusions CONCLUSIONS: It is be possible that rifampicin helps to delay the progression of MSA. Larger numbers of patients with employing sufficient number of controls are necessary to evaluate the effectiveness of rifampicin.

Authors/Disclosures
Masaki Ohyagi PRESENTER	No disclosure on file
Kinya Ishikawa, MD, PhD (Tokyo Med & Dental Univ)	Dr. Ishikawa has nothing to disclose.
Kiyobumi Ota	No disclosure on file
Nozomu Sato, MD (Dept. of neurology & Neurological Science, Tokyo Medical & Dental University)	No disclosure on file
	No disclosure on file
Hidehiro Mizusawa, MD, PhD (National Center of Neurology and Psychiatry)	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��